Fluorescence In situ Hybridization Subgroup Analysis of TRIBUTE, a Phase III Trial of Erlotinib Plus Carboplatin and Paclitaxel in Non – Small Cell Lung Cancer

PURPOSE: TRIBUTE was a phase III trial evaluating the addition of erlotinib to carboplatin and paclitaxel as a first-line treatment for advanced non – small cell lung cancer that did not meet its primary end point of improving overall survival. Here, we assess the value of using epidermal growth fac...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Hirsch, Fred R., Varella-Garcia, Marileila, Dziadziuszko, Rafal, Xiao, Yun, Gajapathy, Sujatha, Skokan, Margaret, Lin, Ming, O’Neill, Vincent, Bunn, Paul A.
Format: Artigo
Idioma:Inglês
Publicat: 2008
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3368373/
https://ncbi.nlm.nih.gov/pubmed/18829515
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-08-0539
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars